Login or Register
What's new
2015-06-23 by programme coordinator Dr Diego Kaski

This educational programme focuses on putative mechanistic links between epilepsy and cardiovascular disease, raises clinically relevant questions about anti-epileptic drug use in the context of cardiac disease, and addresses unresolved issues of practical importance in this area of “neuro-cardiology”.

Read more
2015-03-11 by programme coordinator Prof Juan Carlos Kaski

Managing chronic stable angina pectoris continues to represent a challenge to the practicing physician. Novel anti-angina agents have been incorporated to our therapeutic arsenal in recent years. Ranolazine is one of such agents with novel mechanisms of actions. This programme focuses on the indications, contraindications and practical use of this agent in clinical practice. General practitioners, hospital consultants and clinical-academics contribute their expert views and practical suggestions in this online educational programme.

Read more
Transfemoral vs Transradial approach for PCI - The DRAGON STUDY
2015-10-27 by Prof Juan Carlos Kaski, Dr Pitt Lim
The DRAGON trial (1) recently presented at the recent TCT meeting in San Francisco, which included more than 1700 consecutive patients from 29 centers in China, showed that subjects who were randomized to the transradial …
Read more
Macrolide antibiotic use: cardiotoxicity issues
2015-10-16 by Prof Juan Carlos Kaski, Prof Juan Tamargo
A nationwide based study in Denmark assessed the risk of cardiac death associated with the use of clarithromycin and roxithromycin. Participants included Danish adults, 40-74 years of age, who received seven day treatment courses with …
Read more
New pharmacological compound shown to reduce mortality in heart failure patients approved by FDA
2015-10-16 by Prof Giuseppe Rosano
A drug developed by Novartis for management of patients with heart failure - Entresto (sacubitril/valsartan) - also termed LCZ696, was approved for clinical use by the FDA. LCZ696 was assessed in the PARADIGM-HF trial (1), where …
Read more
2015-11-19
Dr Alexander Niessner speaks to Cardio Debate and Radcliffe Cardiology about anticoagulants in atrial fibrillation and how to identify high risk patients during the ESC Congress 2015 in London, UK.
Read more
2015-11-19
Prof Jean-Pierre Bassand speaks to Cardio Debate and Radcliffe Cardiology about Garfield-AF registry: 2-year data during the ESC Congress 2015 in London, UK
Read more
2015-11-10
Prof Juan Carlos Kaski and Dr Antonio Bayes de Luna speak with Cardio Debate and Radcliffe Cardiology about inter-atrial block and the clinical implications of the Bayes Syndrome during the ESC Congress 2015 in London, …
Read more
2012-07-05
Prof Ali Oto & Prof Antoni Martinez-Rubio talk to cadio-debate.com and discuss about novel anticoagulation agents. A Cardio Debate at the ISCP 17th International Congress.
Read more
2012-07-05
A round table discussion about the potential role of HDL-C in cardiovascular disease prevention: Prof JC Kaski, Prof Anthony S. Weirzbicki, Prof Lina Badimon and Prof Gillian W. Cockerill. Round table at 17th International Congress …
Read more
2012-07-05
Professor Albert Ferro, Kings College, London, UK, and Professor Peter Clemmensen, University of Copenhagen, Denmark discussed the role of antiplatelet agents in the management of acute coronary syndrome. Here, they are joined with Professor Juan …
Read more
Endothelial Dysfunction: Causes & Consequences, the Basis For Rational Management
Dr Luigi Gnudi, King's College of London, London, UK
Link between Endothelial Dysfunction and Systemic Hypertension
Prof Albert Ferro, Professor of Cardiovascular Clinical Pharmacology, Faculty of Life Sciences & Medicine (Cardiovascular Division), King's College London, UK
Endothelial dysfunction in coronary artery disease
Prof Julian Halcox, Professor of Cardiology at the Cardiff University, UK

Leave a Reply